Cartiva Announces GMP Certification By Brazil's ANVISA

ALPHARETTA, Ga.--(BUSINESS WIRE)--Cartiva, Inc., a developer of innovative solutions for the treatment of cartilage damage, osteoarthritis and other musculoskeletal conditions, announced that it has received GMP (Good Manufacturing Practices) certification from Brazil's National Health Surveillance Agency (known as ANVISA) following an inspection and audit of its manufacturing facility in Alpharetta, Georgia. Brazil's GMP regulations, which closely resemble the internationally recognized ISO 13485 standard, require medical device manufacturers to have a quality system for the design, manufacture, packaging, labeling and storage of their products.

“Validation from ANVISA, whose rigorous regulatory standards are similar to those in the United States, represents an important milestone on the path to commercialization of Cartiva.”

“We are pleased with the successful completion of the ANVISA inspection and GMP certification, which is evidence of our commitment to produce innovative products in strict adherence to our quality system,” said Deborah Moore, vice president of regulatory, clinical and quality affairs of Cartiva, Inc. “Validation from ANVISA, whose rigorous regulatory standards are similar to those in the United States, represents an important milestone on the path to commercialization of Cartiva.”

About Cartiva, Inc.

Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative solutions for patients with osteoarthritis, cartilage damage and other musculoskeletal conditions. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Additional information is available on the company’s website at www.cartiva.net.